70% of new precision medicines approved by FDA in past three years were not sponsored by major pharmas

Also in BioCentury’s Deals Report, a trio of biotech deals by GSK, and more

PDAC candidates mostly small molecules against old targets, as a pair of radiopharmaceuticals competes in pancreatic neuroendocrine setting

Clinical Report: Celldex advances in a second urticaria type, Eledon’s mAb helps Type I diabetes patients become insulin-independent, and more

Plus: J&J aiming to replace bladder cancer surgery with TAR-210, and updates from Merck, GlycoMimetics, EyePoint and more

BioCentury identifies new CAR T cell designs, ADCs and other modalities, plus 37 preclinical targets for

Deal brings more momentum for α-emitters, with Fusion’s lead program contrasting Novartis’ β-emitting Pluvicto

Plus: Kyverna lining up a listing next week, and PIPEs for Tectonic, Tyra and Arcus

Johnson & Johnson presents trove of data on bispecific antibody Rybrevant at the ESMO 2023 Congress